HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2

Area of Science:

• Epigenetics
• Molecular Biology
• Biochemistry

Background:

• Histone deacetylases (HDACs) regulate gene transcription by deacetylating histones.
• Class II HDACs are crucial for cellular differentiation and development.
• HDACs are therapeutic targets for various human diseases.

Purpose of the Study:

• To investigate the effect of HDAC inhibitors on class II HDACs in human cells.
• To elucidate the molecular mechanisms underlying HDAC 4 regulation by HDAC inhibitors.
• To explore the interplay between acetylation, deacetylation, and sumoylation pathways.

Main Methods:

• Treatment of human cells with HDAC inhibitors (SAHA, MC1568).
• Analysis of HDAC 4 expression, sumoylation, and degradation.
• Investigation of target gene regulation (RARalpha, TNFalpha).
• Silencing of RANBP2 E3 ligase to assess its role.

Main Results:

• SAHA and MC1568 induce down-regulation of class II HDACs, specifically HDAC 4.
• HDAC 4 down-regulation is mediated by increased sumoylation and subsequent proteasomal degradation.
• HDAC 4 sumoylation enhances its repressive function on target genes, followed by activation upon degradation.
• RANBP2 E3 ligase silencing inhibits HDAC 4 sumoylation and reverts its repression.

Conclusions:

• HDAC inhibitors trigger a cascade involving sumoylation and proteasomal degradation of HDAC 4.
• These findings reveal a crosstalk between acetylation, deacetylation, and sumoylation pathways.
• Class II specific HDAC inhibitors may modulate multiple epigenetic pathways, impacting gene expression.